Copper-binding tripeptide
GHK-Cu
A copper complex also called copper tripeptide-1; topical cosmetic and injectable contexts carry very different evidence and risk questions.
Why it is discussed
Skin, hair, wound, and tissue-remodeling research
GHK-Cu is discussed for skin appearance, hair, extracellular-matrix, and wound-biology claims. Limited topical or cosmetic evidence does not establish broad systemic benefits, and it cannot be used to justify injection.
What it is
Three amino acids, bound to copper.
GHK is a tripeptide: three amino acids—glycine, histidine, and lysine—joined together. It was isolated from human plasma and binds copper(II) ions. GHK-Cu is this copper-peptide complex, not simply another name for copper or for GHK without copper.
Research focuses in part on the extracellular matrix, the network of proteins and other molecules surrounding cells. Collagen is a structural component of that network. Fibroblasts are connective-tissue cells that help produce and maintain it.
How it works
Experimental effects on tissue production and remodeling.
In fibroblast-culture experiments, GHK-Cu increased collagen synthesis. This is a measured cellular response relevant to tissue-repair research; it is not proof of a healing or cosmetic benefit in people.
A separate cell study found increased MMP-2, an enzyme involved in breaking down matrix components, alongside increased release of TIMP-1 and TIMP-2, proteins that regulate matrix-degrading enzymes. This suggests effects on matrix remodeling—the ongoing production, breakdown, and reorganization of tissue—not simply the production of more collagen.
In that experiment, copper ions reproduced the MMP-2 effect while GHK alone did not. This illustrates why the copper complex and the unbound peptide should not be treated as interchangeable. It does not establish copper alone as a treatment.
These findings describe experimental biology, not a fully established therapeutic mechanism in humans. A response in cultured cells cannot establish that a topical product or an injection reaches the relevant tissue, produces a meaningful benefit, or is safe.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Mechanistic, preclinical, and limited topical evidence
Copper-tripeptide biology and limited topical or cosmetic research support narrow questions about skin and tissue remodeling.
Topical findings do not establish injectable benefit, systemic safety, broad anti-aging outcomes, or a human injection regimen.
Regulatory status
Canada and the United States are checked separately.
Health Canada lists injectable GHK-Cu among unauthorized peptide drugs. Cosmetic status depends on formulation and claims and is not injectable-drug authorization.
No FDA-approved injectable product. FDA identifies limited human safety data and aggregation, impurity, and immunogenicity concerns for injectable routes.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.